François Meyer, Chairman of the Board

François graduated from the Swiss Federal Institute of Technology (ETHZ), in Zurich, and studied Biochemistry and Molecular Biology at the University of Zurich.

He received his Ph.D. from the Institute for Molecular Biology. He has spent over 20 years in the pharmaceutical industry.

During the early part of his career, he held various executive positions in R&D at Ciba-Geigy Pharma, wherehe headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business.

After joining Rhone Poulenc Rorer, where he has been head of Global Research, he became head of R&D at Aventis Pharma, France after the merger with Hoechst and lately CEO of Centelion, a biopharmaceutical affiliate company of Aventis Pharma.

He has been member of the board of directors of several privately owned biopharmaceutical companies in the US and in Europe.

François joined TxCell as CEO in 2011. He became Chairman of the Board in 2012 and Head of Research in 2016.

Marie-Laure Garrigues, representing Bpifrance Investissement, Member

Marie-Laure Garrigues, is a pharmacist, former hospital internist in Medical Biology in paris and holds a DEA from the Faculty of Pharmacy of the University of Paris V.

Early in her career, she was the Microbiology Division Manager at Bio-Rad Laboratories, a California diagnostics company, after moving from Sanofi Diagnostics Pasteur, where she held successive management positions.

During her career, she has directed international teams in a variety of programs, including R&D, marketing, and operations.

She specialized in microbiology as a research assistant at the Hospital Necker and the Pasteur Institute, before joining the life science industry.

She has been a Director of Investments at CDC Entreprises since 2008, before joining the management team of Innobio fund in 2009.

Bernard Daugeras, representing Auriga Partners, Member

Bernard is a graduate of the Ecole Polytechnique and has a PhD from the University of Orsay.

Bernard began his career doing research into particle physics at the University of Orsay, the University of California at Berkeley, and CNRS, the French national scientific research center.

He subsequently held senior posts at the French Ministry of Industry and Research, where he was in charge of promoting technology transfer from research institutions and of optimizing relations between Research and Industry.

After 4 years in the Crédit Lyonnais setting up the bank’s Venture Capital arm, he joined Finovelec in 1990 where he was in charge of European Medical Ventures a Life Sciences dedicated Fund.

Co-founder Chairman of the Board of Auriga Partners, Bernard is an expert in Life Sciences and leads the Life Science team at Auriga. He is a member of the French Academy of Technologies.

Thibaut Roulon, representing Bpifrance Participations, Member

Thibaut is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.

He started his career as a scientist in a US biotech company developing cancer immunotherapeutics. In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies.

In 2010, Bioam merged with Bpifrance Investissement (formerly known as CDC Entreprises), a leading French investment firm investing in SMEs and mid-Tier companies. He is in charge of managing investments in life sciences companies (Seed, Venture, IPO, PIPE).

Marie Landel, Independent member

Marie Landel is a French CPA (Expert-comptable), and she holds an MBA from the European Business School (Paris – Frankfurt and London).

After several years in French accounting firms, she moved to Boston in 1990 to start her own practice related to the creation of American subsidiaries of European companies.

Marie has a large experience of accompanying French and European biotechnology companies in the United States and has extensive networks in financial community, specialized in this sector.

Marie is currently on the Board of Directors of Safe Orthopaedics and Cellnovo.

Chevalier de la Légion d’honneur, Marie has been a Foreign Trade Advisors to the French government in the United States for 10 years (CCEF or Conseillers pour le Commerce Extérieur de la France).

David Horn Solomon, Independent member

Dr. David Horn Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York where he received his doctorate in 1991.

He has served as a faculty member at Columbia University’s College of Physicians and Surgeons. From 2003 to 2006, David headed healthcare investing at Carrot Capital Healthcare Ventures in New York.

He has held leadership positions at several biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals, Critical Diagnostics and Vital Sensors. David has extensive experience as a CEO in listed biotech companies, healthcare investing and pharmacology research.

David was CEO of Zealand Pharma A/S (Nasdaq CO: ZEAL) from 2008 to 2015 and on the boards of Onxeo in Paris (NYSE and NASDAQ) and Promosome, in La Jolla, CA, until 2017.

Laurent Arthaud, Observer, non-voting member

A graduate of the École Polytechnique and the French National School of Statistics and Economic Administration, Laurent Arthaud was Vice-President of Aventis Capital, the capital investment subsidiary of pharmaceutical group Aventis, and CEO of Pharmavent Partners, before joining CDC Entreprises in 2006 as Director in charge of new developments.

In 2009, he became Deputy CEO at CDC Entreprises, Manager of InnoBio fund.

Laurent Higueret, Observer, non-voting member

Laurent joined Bpifrance’s Large Venture Fund in early 2014 as an Investment Director, focusing primarily on healthcare investments.

He currently serves on the Board of Directors of Poxel and TxCell, and follows Bpifrance’s investments in Cerenis and DBV Technologies. Previously, he spent six years as an investment banker with BNP Paribas’ Healthcare M&A Group, and built a healthcare services startup.

Laurent Higueret is a Doctor of Pharmacy from the University of Bordeaux and holds a Master Degree in Finance from EM Lyon Business School.